WIDE-RANGE FOR OPTIMAL CONCENTRATION OF FOLINIC ACID IN FLUOROURACIL MODULATION - EXPERIMENTAL-DATA ON HUMAN TUMOR-CELL LINES

被引:14
作者
BECK, A
ETIENNE, MC
CHERADAME, S
FISCHEL, JL
FORMENTO, P
GUILLOT, T
MILANO, G
机构
[1] CTR ANTOINE LACASSAGNE,F-06054 NICE,FRANCE
[2] LEDERLE LABS,F-94578 RUNGIS,FRANCE
关键词
D O I
10.1016/0959-8049(94)E0063-A
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical use of the fluorouracil (FU)-folinic acid (FA) combination is hampered by the still open choice of the optimal schedule, with marked controversy as concerns the optimal FA dose. This in vitro study on FU-FA combinations in 17 human cancer cell lines, representative of tumour types responding to FU-FA treatment, reassesses the notion of the optimal FA concentration. Cells were exposed for 5 days to various FU-FA concentrations (0.07-77 mu M, 14 concentrations, for FU; and 0.0025-100 mu M for FA). The growth inhibition was assessed by the MTT test. The investigated cell lines exhibited FU IC50 ranging from 0.4 to 38.9 mu M (median 3.7 mu M). In six out of 17 cell lines investigated, the addition of FA did not result in a substantial enhancement of FU cytotoxicity (group 1). For the remaining 11 cell lines responding to FA supplementation (group 2), the maximal enhancement factor ranged from 3 to 8, meaning that in the presence of optimal FA concentration, the efficient FU concentration (IC50) was reduced by between 3 and 8 as compared to the efficient FU concentration without FA supplementation. For cell lines responding to FA supplementation, the optimal FA concentrations ranged from 10(-7) to 4 x 10(-4) M (4000-fold range) with a median value at 9.6 x 10(-7) M. Distribution of cell doubling time was not significantly different between group 1 and group 2. In contrast, the FU IC50 were significantly different (P = 0.02) between group 1 (median 7.4 mu M) and group 2 (median 2.2 mu M), thus indicating that cell lines with the greatest FU cytotoxicity enhancement by FA were those intrinsically sensitive to FU and vice versa.
引用
收藏
页码:1522 / 1526
页数:5
相关论文
共 24 条
[1]  
BOARMAN DM, 1992, CANCER RES, V52, P36
[2]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[3]  
DEBRAUD F, 1992, ANN ONCOL S5, V3, P132
[4]   PROSPECTIVE RANDOMIZED COMPARISON OF FLUOROURACIL VERSUS FLUOROURACIL AND HIGH-DOSE CONTINUOUS INFUSION LEUCOVORIN CALCIUM FOR THE TREATMENT OF ADVANCED MEASURABLE COLORECTAL-CANCER IN PATIENTS PREVIOUSLY UNEXPOSED TO CHEMOTHERAPY [J].
DOROSHOW, JH ;
MULTHAUF, P ;
LEONG, L ;
MARGOLIN, K ;
LITCHFIELD, T ;
AKMAN, S ;
CARR, B ;
BERTRAND, M ;
GOLDBERG, D ;
BLAYNEY, D ;
ODUJINRIN, O ;
DELAP, R ;
SHUSTER, J ;
NEWMAN, E .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :491-501
[5]   CONTINUOUS INFUSION HIGH-DOSE LEUCOVORIN WITH 5-FLUOROURACIL AND CISPLATIN FOR UNTREATED STAGE-IV CARCINOMA OF THE HEAD AND NECK [J].
DREYFUSS, AI ;
CLARK, JR ;
WRIGHT, JE ;
NORRIS, CM ;
BUSSE, PM ;
LUCARINI, JW ;
FALLON, BG ;
CASEY, D ;
ANDERSEN, JW ;
KLEIN, R ;
ROSOWSKY, A ;
MILLER, D ;
FREI, E .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (03) :167-172
[6]   NO EFFECT OF DOSE, HEPATIC-FUNCTION, OR NUTRITIONAL-STATUS ON 5-FU CLEARANCE FOLLOWING CONTINUOUS (5-DAY), 5-FU INFUSION [J].
FLEMING, RA ;
MILANO, GA ;
ETIENNE, MC ;
RENEE, N ;
THYSS, A ;
SCHNEIDER, M ;
DEMARD, F .
BRITISH JOURNAL OF CANCER, 1992, 66 (04) :668-672
[7]   THE COST OF FOLINIC ACID [J].
HEALY, JB .
BRITISH JOURNAL OF CANCER, 1990, 62 (03) :467-467
[8]  
HOUGHTON JA, 1981, CANCER RES, V41, P144
[9]  
HOUGHTON JA, 1990, CANCER RES, V50, P3940
[10]   FACTORS THAT INFLUENCE THE THERAPEUTIC ACTIVITY OF 5-FLUOROURACIL [6RS]LEUCOVORIN COMBINATIONS IN COLON ADENOCARCINOMA XENOGRAFTS [J].
HOUGHTON, JA ;
WILLIAMS, LG ;
LOFTIN, SK ;
CHESHIRE, PJ ;
MORTON, CL ;
HOUGHTON, PJ ;
DAYAN, A ;
JOLIVET, J .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (06) :423-432